| Pharmaceutical Information |
| Drug Name |
Adefovir dipivoxil |
| Drug ID |
BADD_D00044 |
| Description |
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir. |
| Indications and Usage |
Indicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AF08 |
| DrugBank ID |
DB00718
|
| KEGG ID |
D01655
|
| MeSH ID |
C106812
|
| PubChem ID |
60871
|
| TTD Drug ID |
D0ML1F
|
| NDC Product Code |
53104-7602; 42794-003; 60505-3947; 61958-0501 |
| UNII |
U6Q8Z01514
|
| Synonyms |
adefovir dipivoxil | adefovir depivoxil | 9-(2-((-bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine | Hepsera | Preveon | GS 840 | GS-0840 |
|
| Chemical Information |
| Molecular Formula |
C20H32N5O8P |
| CAS Registry Number |
142340-99-6 |
| SMILES |
CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
